| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/30/2004 | WO2003031574A3 Elastase inhibitors |
| 09/30/2004 | WO2003026645A8 Tetrapeptide derivative crystals |
| 09/30/2004 | US20040194160 Expression vector comprising nucleotide sequences coding glucocorticoid-induced leucine-zipper family related protein (GILR) and tissue specific regulatory regions for transformation and generation of animal models to identify glucocorticoid hormones regulated genes associated with apoptosis control |
| 09/30/2004 | US20040194159 Cloning pigs using donor nuclei from differentiated cells |
| 09/30/2004 | US20040194155 Comprises hepatitis b viral nucleotide sequences coding mutant reverse transcriptase for use in developing antibodies to prevent or treat hepatitis viral infection; immunotherapy; |
| 09/30/2004 | US20040192901 Using superoxide dismutase to identify modulators for treatment of diabetes, scrapies, transmissible spongiform encephalopathies and alzheimer's diseases |
| 09/30/2004 | US20040192898 Anti-abeta antibodies |
| 09/30/2004 | US20040192891 Mammalian cytokines; related reagents and methods |
| 09/30/2004 | US20040192889 Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof |
| 09/30/2004 | US20040192886 for use in the treatment and prevention of nervous system, epileptic, pain and vision defects; neuromuscular blocking agents; local anesthetic ; analgesics; neuroprotective agents |
| 09/30/2004 | US20040192742 Antiarthritic agents; muscular dystrophy; antiinflammatory agents; glomerulonephritis; malaria; oral diseases |
| 09/30/2004 | US20040192685 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| 09/30/2004 | US20040192658 Compositions and methods of using collajolie |
| 09/30/2004 | US20040192654 use of nucleoside analogues as an effective treatment for acute or chronic myelogenous leukemia; (-)- beta -L-Dioxolane-Cytidine ( beta -L-oddC); (-)- beta -Dioxolane-5-fluoro-Cytidine (5-FddC) |
| 09/30/2004 | US20040192633 Antisense modulation of short heterodimer partner-1 expression |
| 09/30/2004 | US20040192632 comprised of a VEGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a VEGF Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with the Non-Immunogenic or High Molecular Weight Compound |
| 09/30/2004 | US20040192630 nucleic acid constructs containing a HexB encoding element and a HexA encoding element; used in the treatment of Tay-Sachs and Sandoff disease; delivering a vector to a brain cell |
| 09/30/2004 | US20040192629 Selectively inhibit the mutant while retaining wild-type gene expression to treat diseases caused by dominant mutants such as amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, and Parkinson's disease; administering to the cell an siRNA specific for the target allele |
| 09/30/2004 | US20040192628 gene expression inhibition of the kinase to prevent neovascularization, treat cancer |
| 09/30/2004 | US20040192626 siNA molecule comprising a double-stranded structure that down-regulates expression of a target nucleic acid, wherein said siNA molecule does not require a 2'-hydroxyl group containing ribonucleotide; treating viral diseases such as SARS (severe acute respiratory syndrome virus), herpes, hepatitis, HIV |
| 09/30/2004 | US20040192625 administering an isolated nucleic acid molecule of the beta 2AR gene; gene therapy; beta 2-adrenergic receptors ( beta 2AR) gene |
| 09/30/2004 | US20040192624 UDP-glucuronosyltransferases (UGTs), UGT1A1 being a bilirubin-specific isozyme; inducing UGT1A1 isoform expression for treating unconjugated hyperbilirubinemia by administering ritonavir; side effect reduction of AIDS drugs such as indinavir, atazanavir, amphotericin B/cholesteryl sulfate complex |
| 09/30/2004 | US20040192611 amino acid sequence GVAWWM*; and GVAWWM*Y; wherein M* is methionine sulfoxide; use reducing oxidative degradation of fats or oils, or providing an antioxidant to a person in either pharmaceutical or dietary compositions |
| 09/30/2004 | US20040192610 For treating disorders regulated at neuronal nicotinic acetylcholine receptors, including cardiovascular disorders, gastric motility disorders, urinary incontinence, nicotine addiction, mood disorders and small cell lung carcinoma |
| 09/30/2004 | US20040192609 Peptides binding gp120 of HIV-1 |
| 09/30/2004 | US20040192608 Treatment of obesity |
| 09/30/2004 | US20040192607 Transcriptional regulation of the human beta3-adrenergic receptor gene |
| 09/30/2004 | US20040192606 treating an infection or ischemic wound in a mammal by administering relaxin; treating ischemic ulcer with recombinant human relaxin (H2) for example |
| 09/30/2004 | US20040192605 Methods and compositions for healing and repair of articular cartilage |
| 09/30/2004 | US20040192603 Substantially non-immunogenic injectable collagen |
| 09/30/2004 | US20040192602 Comprises enhanced blood protein with for use in treatment of bleeding disorders |
| 09/30/2004 | US20040192600 Use of a specific COX-2 inhibitor, and/or a pharmaceutically acceptable salt and lung surfactant (SP-B and SP-C) for the production of medicaments for the treatment and/or prophylaxis of infant respiratory distress syndrome and adult respiratory distress syndrome |
| 09/30/2004 | US20040192598 Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase |
| 09/30/2004 | US20040192597 Nucleic acids and corresponding proteins entitled 202P5A5 useful in treatment and detection of cancer |
| 09/30/2004 | US20040192596 Therapeutic fibrin-derived peptides and uses thereof |
| 09/30/2004 | US20040192595 Treatment of lung disorders |
| 09/30/2004 | US20040192594 Modified neurotoxins as therapeutic agents for the treatment of diseases and methods of making |
| 09/30/2004 | US20040192593 Protease resistant ti-growth hormone releasing hormone |
| 09/30/2004 | US20040192592 Using gene therapeutic vector containing chlamydial regulatory protein to transform, treat and prevent atherosclerosis |
| 09/30/2004 | US20040192591 Composition for treating Chlamydia infections and method for identifying same |
| 09/30/2004 | US20040192590 Method of using lectins for contraception, prophylaxis against diseases transmittable by sexual contact, and therapy of such diseases, and apparatus for administering lectins |
| 09/30/2004 | US20040192589 Production of high molecular mass lectins |
| 09/30/2004 | US20040192588 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration |
| 09/30/2004 | US20040192586 Materials and methods relating to anti-inositolphosphoglycan antibodies |
| 09/30/2004 | US20040192581 Applying a topical formulations prepared from lysostaphin and lantibiotics such as nisin that are effective in treating dermatological and wound infections without disrupting the balance of non-pathogenic and pathogenic populations of skin flora |
| 09/30/2004 | US20040192580 Regulation of human ceramide kinase |
| 09/30/2004 | US20040191926 Ptp1b inhibitors and ligands |
| 09/30/2004 | US20040191904 Antisense modulation of src-c expression |
| 09/30/2004 | US20040191898 Trangenic diploid cell comprising mutation in kinase allele for use in screening modulator for treatment of anxiety, addiction, withdrawal syndrome, skeletal muscle spasms, convulsive seizures and epilepsy |
| 09/30/2004 | US20040191886 Nucleotide sequences encoding bovine respiratory syncytial virus immunogenic proteins |
| 09/30/2004 | US20040191868 Nucleotide sequence coding canine interleukin -5 protein for use in identifying immunomodulators which treat or prevent autoimmune, allergic, infectious, inflammatory and graft rejection disorders in animals |
| 09/30/2004 | US20040191865 Using transgenic cells for propagation of heterologous proteins; bioreactors |
| 09/30/2004 | US20040191857 Process for the preparation of angiotensis converting enzyme (ACE) inhibitors and its use |
| 09/30/2004 | US20040191843 Cytotoxic mixture comprising polypeptides for treatment and prevention of cell proliferfative disorders |
| 09/30/2004 | US20040191840 Using immunoglobulins to inactivate viricidal and antitumor activities of huma n type interferon for preventing autoimmunity and graft rejection; immunosuppressants |
| 09/30/2004 | US20040191829 Comprises peptide associated with sugar transport protein for identifying modulators for treatment and prevention of cell proliferative disorder |
| 09/30/2004 | US20040191827 Modulators of the hypocretin system and methods of screening therefor |
| 09/30/2004 | US20040191826 Dipeptidyl peptidases |
| 09/30/2004 | US20040191820 Using high throughput assay for detection and identification of modulators of telomeric complex binding activity; diagnosis and treatment of cell proliferative and age related disorders; antiproliferative agent |
| 09/30/2004 | US20040191818 Compositions and methods for diagnosing and treating autoimmune diseases |
| 09/30/2004 | US20040191791 Comprises nucleotide sequences coding sodium voltage gated channels for identifying modulators for treatment of epilepsy; diagnosis of seizure disorders |
| 09/30/2004 | US20040191773 Oligoribonucleotides and ribonucleases for cleaving RNA |
| 09/30/2004 | US20040191763 HBV mutations associated with reduced susceptibility to adefovir |
| 09/30/2004 | US20040191756 Transgenic rodent for diagnosing and identifying modulator for treatment and prevention inflammatory disorders |
| 09/30/2004 | US20040191330 Daily skin care regimen |
| 09/30/2004 | US20040191325 Protecting proteins from organic solvent denaturating during encapsulation; controlling release rate and profile; application to viruses, bacteria and/or cells; diagnosis kit |
| 09/30/2004 | US20040191320 Pulmonary formulation |
| 09/30/2004 | US20040191305 Entrapping in phosphatidylcholine component; room temperature transdermal delivery system; long shelf life |
| 09/30/2004 | US20040191303 Inhibiting adhesion of cells to activated vascular endothelium from bloodstream; proteins and glycoproteins isolated from human or animal amniotic fluid, serum or urine |
| 09/30/2004 | US20040191291 Composition and method for nerve regeneration |
| 09/30/2004 | US20040191273 Methods and compositions for obtaining disease protection for economically important animals |
| 09/30/2004 | US20040191272 Methods and reagents for vaccination which generate a CD8 T cell immune response |
| 09/30/2004 | US20040191270 Vaccine compositions |
| 09/30/2004 | US20040191268 Isolated, synthetic or recombinant nonapeptide of a minor Histocompatability antigen HA-1 comprising the sequence valine-leucine-X-aspartic acid-aspartic acid-leucine-leucine-glutamic acid-alanine wherein X is arginine or histidine; bone marrow transplants; graft versus host disease; leukemia |
| 09/30/2004 | US20040191267 Neisseria spp. polypeptide, nucleic acid sequence and uses thereof |
| 09/30/2004 | US20040191263 Enteral compositions for the prevention and/or treatment of sepsis |
| 09/30/2004 | US20040191261 Genetically engineered fusion protein comprising fibrin/fibrinogen binding moiety such as endothelial growth factor (VEGF165) C-terminal domain fused to a wound healing agent such as leptin |
| 09/30/2004 | US20040191257 Pharmaceutical compositions comprising herpes virus entry receptor protein |
| 09/30/2004 | US20040191253 Treating vascular injuries resulting from angioplasty, endarterectomy, reduction atherectomy or anastomosis of a vascular graft; administering anti-platelet derived growth factor receptor antibody with heparin |
| 09/30/2004 | US20040191251 Rescue of gonadotropin releasing hormone receptor mutants |
| 09/30/2004 | US20040191247 Use of il-18 inhibitors for treating or preventing cns injuries |
| 09/30/2004 | US20040191240 Blocking a p75 signal transduction pathway; treatment of brain and spinal cord injuries |
| 09/30/2004 | US20040191239 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 09/30/2004 | US20040191238 Administering to patient an agent which triggers anion efflux in respiratory tissues via activation of a secretin receptor |
| 09/30/2004 | US20040191237 Mixture of proteases from Aspergillus oryzae and Bacillus subtilis and an Aspergillus niger lipase; indigestion, sour stomach, dyspepsia, and other gastrointestinal disorders related to poor protein digestion |
| 09/30/2004 | US20040191231 Medicinal product for the promotion of wound healing |
| 09/30/2004 | US20040191230 Pharmaceutical composition for the diagnosis, prevention or treatment of a tumoral pathology comprising an agent modulating the polymerization state of actin |
| 09/30/2004 | US20040191223 Combinatorial methods for inducing cancer cell death |
| 09/30/2004 | US20040191221 Delivering heterologous gene to a periosteal cell of a mammal; gene expression; bone disorders, osteoarthritis and osteoporosis; antiinflammatory agents |
| 09/30/2004 | US20040191219 HSA-free formulations of interferon-beta |
| 09/30/2004 | US20040191218 Pharmaceutical compositions and methods for treating cancer |
| 09/30/2004 | US20040191217 Orally administering interferon-tau to intestinal tract to produce measureable increase in patient's blood level of 2*,5*-oligoadenylate synthetase (OAS); autoimmune disease, viral infection and cancer treatment |
| 09/30/2004 | US20040191216 Medicines including interferon and administering system thereof |
| 09/30/2004 | US20040191215 Drug reservoirs containing therapeutic agent(s) effective to attract desired cells to the tissue site; to stimulate activity, e.g., proliferation, differentiation, and/or release of biological factors to promote a desired activity, in the attracted cells; to prolong survival of attracted cell |
| 09/30/2004 | US20040191211 Tissue-specific transporter inhibitor |
| 09/30/2004 | US20040191203 Cosmetic or dermatological composition comprising n-acylaminoamide derivatives |
| 09/30/2004 | US20040191175 Radio-Opaque polymer biomaterials |
| 09/30/2004 | CA2855229A1 Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| 09/30/2004 | CA2790689A1 Fvii or fviia variants |
| 09/30/2004 | CA2743539A1 Angiotensin-converting enzyme inhibitory peptides |